Treatment of adult patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency: A clinical practice audit

Endocrine Practice

Volumn 9, Issue 5, 2003, Pages 347-352

  Li, Howard Y ^a   Dahir, Kathryn McCrystal ^a   Blevins Jr , Lewis S ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEXAMETHASONE; GLUCOCORTICOID; HYDROXYPROGESTERONE; STEROID 21 MONOOXYGENASE;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CONGENITAL ADRENAL HYPERPLASIA; FEMALE; GENETICS; HUMAN; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

17-ALPHA-HYDROXYPROGESTERONE; ADOLESCENT; ADRENAL HYPERPLASIA, CONGENITAL; ADULT; AGED; DEXAMETHASONE; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; STEROID 21-HYDROXYLASE; TREATMENT OUTCOME;

EID: 2142713942     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/ep.9.5.347     Document Type: Article

References (23)

1. Miller WL. Congenital adrenal hyperplasia in the adult patient. Adv Intern Med. 1999;44:155-173.
2. Speiser PW. Congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Endocrinol Metab Clin North Am. 2001;30:31-59, vi.
3. White PC, Speiser PW. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency [erratum in Endocr Rev. 2000;21:550]. Endocr Rev. 2000;21:245-291.
4. Donohoue PA, Parker K, Migeon CJ. Congenital adrenal hyperplasia. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. 7th ed. New York: McGraw-Hill, 1995: 2929-2966.
5. Migeon CJ. Diagnosis and treatment of adrenogenital disorders. In: DeGroot LJ, Besser GM, Marshall JC, et al, eds. Endocrinology. 2nd ed. Philadelphia: WB Saunders, 1989:1676-1704.
6. Wilkins L, Lewis RA, Klein R, Rosemberg E. The suppression of androgen secretion by cortisone in a case of congenital adrenal hyperplasia. Bull Johns Hopkins Hosp. 1950;86:249-252.
7. Bartter FC, Albright F, Forbes AP, Leaf AP, Dempsey E, Carroll E. The effects of adrenocorticotrophic hormone and cortisone in the adrenogenital syndrome associated with congenital adrenal hyperplasia: an attempt to explain and correct its disordered hormonal pattern. J Clin Invest. 1951;30:237-251.
8. Hansen JW, Loriaux DL. Variable efficacy of glucocorticoids in congenital adrenal hyperplasia. Pediatrics. 1976;57:942-947.
9. Grant DB, Dillon MJ, Atherden SM, Levinsky RJ. Congenital adrenal hyperplasia: renal and steroid values during treatment. Eur J Pediatr. 1977;126:86-96.
10. Smith R, Donald RA, Espiner EA, Glatthaar C, Abbott G, Scandrett M. The effect of different treatment regimens on hormonal profiles in congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1980;51:230-236.
11. Horrocks PM, London DR. A comparison of three glucocorticoid suppressive regimes in adults with congenital adrenal hyperplasia. Clin Endocrinol (Oxf). 1982;17:547-556.
12. Heazelwood VJ, Galligan JP, Cannell GR, Bochner F, Mortimer RH. Plasma cortisol delivery from oral cortisol and cortisone acetate: relative bioavailability. Br J Clin Pharmacol. 1984;17:55-59.
13. Petersen KE. The production of cortisol and corticosterone in children. Acta Paediatr Scand Suppl. 1980;281:1-38.
14. Rosler A, Levine LS, Schneider B, Novogroder M, New MI. The interrelationship of sodium balance, plasma renin activity and ACTH in congenital adrenal hyperplasia. J Clin Endocrinol Metab. 1977;45:500-512.
15. Hughes IA, Wilton A, Lole CA, Gray OP. Continuing need for mineralocorticoid therapy in salt-losing congenital adrenal hyperplasia. Arch Dis Child. 1979;54:350-355.
16. Esteban NV, Loughlin T, Yergey AL, et al. Daily cortisol production rate in man determined by stable isotope dilution/mass spectrometry. J Clin Endocrinol Metab. 1991;72:39-45.
17. Kraan GP, Dullaart RP, Pratt JJ, Wolthers BG, Drayer NM, De Bruin R. The daily cortisol production reinvestigated in healthy men: the serum and urinary cortisol production rates are not significantly different. J Clin Endocrinol Metab. 1998;83:1247-1252.
18. Zelissen PM, Croughs RJ, van Rijk PP, Raymakers JA. Effect of glucocorticoid replacement therapy on bone mineral density in patients with Addison disease. Ann Intern Med. 1994;120:207-210.
19. Peacey SR, Guo CY, Robinson AM, et al. Glucocorticoid replacement therapy: are patients overtreated and does it matter? Clin Endocrinol (Oxf). 1997;46:255-261.
20. Kehlet H, Binder C, Blichert-Toft M. Glucocorticoid maintenance therapy following adrenalectomy: assessment of dosage and preparation. Clin Endocrinol (Oxf). 1976;5:37-41.
21. Scott RS, Donald RA, Espiner EA. Plasma ACTH and cortisol profiles in addisonian patients receiving conventional substitution therapy. Clin Endocrinol (Oxf). 1978;9:571-576.
22. Groves RW, Toms GC, Houghton BJ, Monson JP. Corticosteroid replacement therapy: twice or thrice daily? J R Soc Med. 1988;81:514-516.
23. Hughes IA, Read GF. Menarche and subsequent ovarian function in girls with congenital adrenal hyperplasia. Horm Res. 1982;16:100-106.